Cardiomyocyte injury: mechanism of doxorubicin toxicity effects

Pathophysiology of Cell Injury Journal  Volume 3, Issue 2, pages 73-82 December 2014

Monica Vlaia; Mariela Hoang; Veronica Urzúa; Hugo Scammells; Sevgi González-Hernández


Doxorubicin is part of a group of anthracycline antibiotics used in many treatment of solid and hematological malignancy. Doxorubicin use is limited by cumulative, dose-related, progressive myocardial cell injury that may lead to cardiotoxicity. The cardiotoxicity induced by doxorubicin appears to be a multi-factorial process and many mechanisms have been proposed and studied. The objective of this study is to approve the role of toll-like receptor (TLR)-3 in mechanism of doxorubicin toxicity. Wild-type male adult mice and knock-out mice were used. To investigated the role of TLR3, MAPK in the doxorubicin cardiotoxcity, MAPK protein assay by using western blot in mice. Taken together our findings demonstrate for the first time a relevant role of TLR3 in the development of doxorubicin induces cardiotoxicity under experimental condition. Further, studies using therapeutic interventions such as pharmacological TLR3 inhibition may be.

Keywords: Doxorubicin; MAPK/TRIF; Cardiac cell injury; Hemodynamic study

Full Text-PDFReferences

Choose an option to access this article:
1. Purchase this article at rate $55.00 and received Full-Text/PDF
You will have online immediate access to article following the completion of this purchase and you may download and print a copy of each article for your personal use.
2. Full-Text/PDF access through your institution subscription password:


1. Panjrath GS, Patel V, Valdiviezo CI, et al. Potentiation of doxorubicin cardiotoxicity by iron loading in a rodent model. J Am Coll Cardiol 2007; 49:2457-2464. [PubMed]

2. Robert J. Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: predictiveness and pitfalls. Cell Biol Toxicol 2007; 23(1):27-37. [PubMed]

3. Platel D, Pouna P, Bonoron-Adèle S, Robert J. Preclinical evaluation of the cardiotoxicity of taxane-anthracycline combinations using the model of isolated perfused rat heart. Toxicol Appl Pharmacol 2000;163(2):135-40. [PubMed]

4. Oliveira Paulo J, Bjork James A, Santos MS, et al. Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity. Toxicol Appl Pharmacol 2004; 200:159-168. [Abstract/Full-text]

5. Olson RD, Mushlin PS. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB 1990, 4:3076-3086. [PubMed]

6. Muzaffar Iqbal, Kiran Dubey, Tarique Anwer, et al. Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats. Pharmacol Rep 2008; 60:382-390. [PubMed]

7. Yousif NG, Ao L, Li J, et al. Myocardial Tissue TLR4 Plays a Major Role in Mediating Myocardial Injury Following Cold Ischemia and Reperfusion Through Up-regulation Of MCP-1. ASC 2011 Abstract, Quick shot. Transplant Immunol (Transplant/Immunology) 

8. Arola OJ, Saraste A, Pulkki K, et al. Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res 2000; 60:1789–1792.

9. Shinozawa S, Gomita Y, Araki Y. Effect of high-dose α-tocopherol acetate pretreatment on adriamycin (doxorubicin) induced toxicity and tissue distribution. Physiol Chem Phys Med NMR 1988; 20:329-335. [PubMed]

10. Nozaki N, Shishido T, Takeishi Y. Modulation of doxorubicin-induced cardiac dysfunction in toll-like receptor-2-knockout mice. Circulation 2004; 110(18):2869-2874. [Abstract/Full-text]

11. Akira S, Takeda K, Kaisho T. Toll-like receptors. critical proteins linking innate and acquired immunity. Nat Immunol 2001; 2:675–680. [PubMed]

12. Baumgarten G, Knuefermann P, Nozaki N, et al. In vivo expression of proinflammatory mediators in the adult heart after endotoxin administration: the role of toll-like receptor-4. J Infect Dis 2001; 183:1617–1624. [Abstract/Full-text]

13. Lien E, Means TK, Heine H, et al. Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. J Clin Invest 2000;105:497-504. [PubMed]

14. Kirschning CJ, Wesche H, Ayres TM, Rothe M. Human Toll-like receptor 2 confers responsiveness to bacterial lipopolysaccharide. J Exp Med 1998;188:2091–2097. [PubMed]

15. Heine H, et al. Cutting edge: cells that carry a null allele for Toll-like receptor 2 are capable of responding to endotoxin. J Immunol 1999;162:6971–6975. [PubMed]

16. Yousif NG, Al-amran FG. Novel Toll-like receptor-4 deficiency attenuates trastuzumab (Herceptin) induced cardiac injury in mice. BMC cardiovascular disorders 2011; 11(1):62. [PubMed]

17. Ha T, Li Y, Hua F. Reduced cardiac hypertrophy in toll-like receptor 4-deficient mice following pressure overload. Cardiovasc Res 2005; 68(2):224-234. [Abstract/Full-Text]

18. Liu B, Zheng H, Stoilova D, Sun S, Li Z. Cell surface expression of an endoplasmic reticulum resident heat shock protein pg96 triggers MyD88-dependent systemic autoimmune diseases. Proc Natl Acad Sci USA 2003;100:15824–15829. [Abstract/Full-Text]

19. Tsan MF, Gao B. Endogenous ligands of Toll-like receptors. J Leukoc Biol 2004;76:514–519. [Abstract/Full-Text]

20. Haase R, Kirschning CJ, Sing A, et al. A dominant role of toll-like receptor 4 in the signaling of apoptosis in bacteria-faced macrophages. J Immunol 2003;171:4294–4303. [Abstract/Full-Text]

21. Zhang D, Gaussin V, Taffet GE, et al. TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice. Nat Med 2000; 6:556–563. [PubMed]

22. Medzhitov R, Preston-Hurlburt P, Janeway CA., Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388:394–397. [PubMed]

23. Ohashi K, Burkart V, Flohe S, Kolb H. Cutting Edge: Heat Shock Protein 60 Is a Putative Endogenous Ligand of the Toll-Like Receptor-4 Complex . J Immunol 2000;164:558–561. [PubMed]


Print Friendly, PDF & Email